# Sol-Gel Technologies Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Sol-Gel Technologies Ltd.). ## Overview Sol-Gel Technologies Ltd. is an Israel-based dermatology and pharmaceutical company that develops and commercializes prescription treatments for skin diseases. Its business centers on branded topical products and product candidates, with commercialization carried out directly in some markets and through licensing partners in others. ## Products & services • TWYNEO® acne treatment • EPSOLAY® rosacea treatment • SGT-610 (patidegib gel, 2%) • Licensing and territory commercialization rights • Dermatology product development and clinical trials - **Commercial dermatology products** (85%) — Approved prescription skin treatments sold through partners and licensees in multiple territories. - **Clinical-stage product candidates** (10%) — Investigational dermatology programs being advanced through clinical development. - **Licensing and royalties** (5%) — Upfront, milestone, and royalty income from out-licensing commercial rights by territory. - TWYNEO® acne treatment - EPSOLAY® rosacea treatment - SGT-610 (patidegib gel, 2%) - Licensing and territory commercialization rights - Dermatology product development and clinical trials ## Customers Sol-Gel sells into the dermatology prescription market, so the end users are patients treated by dermatologists and other prescribing physicians. Its commercial counterparties are pharmaceutical partners and licensees that obtain rights to market TWYNEO® and EPSOLAY® in specific countries or regions. Revenue is therefore driven by both product demand in local markets and the pace of partner-led launches. - **Dermatology prescribers** (primary) — Dermatologists and other physicians prescribe TWYNEO® and EPSOLAY® for acne and rosacea. - **Territory license partners** (primary) — Pharma partners buy commercialization rights, pay milestones, and generate royalties in their markets. - **Patients** (secondary) — Patients are the end users of the prescription products, with demand driven by disease prevalence and physician adoption. - **Clinical research sites** (secondary) — Sites and investigators support development of SGT-610 and other pipeline studies. - Dermatologists prescribing acne and rosacea therapies - Pharmaceutical licensees commercializing products by territory - Healthcare patients needing topical prescription treatments - Regional partners seeking dermatology product rights - Clinical investigators and trial sites for SGT-610 ## Geography Sol-Gel is headquartered in Ness Ziona, Israel, and its commercial footprint spans a mix of direct and partner-led international markets. The company has signed licensing agreements covering parts of Europe, South Africa, South Korea, Australia and New Zealand, with additional rights in India, China, Hong Kong, Macau, Taiwan, Israel, and Canada. This geography mix makes the business dependent on partner execution and regulatory timing across multiple jurisdictions. - Headquartered in Ness Ziona, Israel - Commercial rights licensed across multiple international territories - Europe is a key partnered market for TWYNEO® and EPSOLAY® - Asia-Pacific exposure includes South Korea, Australia and New Zealand - Additional rights cover India, China, Canada and Israel ## Strategy Sol-Gel’s strategy is to expand TWYNEO® and EPSOLAY® through territory-by-territory licensing agreements that can generate upfront, milestone and ongoing royalty income. At the same time, it is advancing SGT-610 through clinical development to broaden the pipeline beyond marketed dermatology assets. - **Expand licensing coverage for TWYNEO® and EPSOLAY®** (short-term) — Broader territory coverage increases upfront payments, milestone potential and future royalties. - **Convert signed agreements into product launches** (medium-term) — Royalties depend on partner commercialization and market launch timing. - **Advance SGT-610 through clinical development** (medium-term) — Pipeline success could create a new future dermatology franchise beyond current products. - License commercial rights market by market - Collect upfront and milestone payments from partners - Build recurring royalty revenue after product launches - Advance SGT-610 through late-stage development - Use partnerships to extend reach without full local infrastructure ## Risks Sol-Gel depends on the success of clinical development, regulatory approvals, and partner commercialization, all of which can delay or prevent revenue generation. Because much of the business is licensed internationally, execution risk is shared with third parties and exposed to local market, regulatory and launch-timing uncertainty. - **Clinical development risk for SGT-610** [high] — The product candidate must succeed in late-stage trials to support future value creation. - **Regulatory approval and timing risk** [high] — Commercialization depends on obtaining approvals and avoiding delays in target markets. - **Partner commercialization risk** [high] — Royalties and milestones depend on licensees successfully launching and marketing the products. - **Geopolitical exposure in Israel** [medium] — The company is headquartered in Israel and referenced regional conflict as a business risk. - Clinical trial failure could reduce the value of SGT-610 - Regulatory delays can postpone launches and partner milestones - Partner execution risk affects royalties and market penetration - International licensing exposes the company to country-specific rules - Dermatology product adoption can be slower than expected ## Accounting The company recognizes revenue from product sales and collaboration-type arrangements, so timing can vary with partner shipments, launches and milestone events. Because the business also carries a clinical pipeline, investors should watch the accounting for development spending, share-based compensation, and any fair value changes in marketable securities or other financial assets. - **Revenue recognition** — Can cause uneven quarterly revenue - **Clinical development costs** — Affects operating loss and cash burn - **Fair value of marketable securities** — Impacts non-operating income - **Share-based compensation** — Affects operating expenses and equity - Revenue mix may include product sales, royalties and milestone fees - Launch timing can create quarter-to-quarter revenue volatility - R&D expense reflects ongoing clinical trial and development spend - Marketable securities can affect reported financial income - U.S. GAAP interim reporting requires judgment on accruals and estimates --- *Last updated: 2026-09-28T12:14:06.123023+00:00*